The recent flurry of drug approvals has markedly altered the treatment landscape in AML providing patients with new opportunities. The space is getting more exciting as improved genetic testing, combinations of targeted therapies, and the advancement of immunotherapies will finally provide physicians options to advance beyond Walkman-era treatments.
Interest in the EGFR Lung cancer space initially started with the isolation of Epidermal growth factor (EGF) gene by Stanley Cohen in 1962 as a protein extracted from the mouse submaxillary gland that accelerated incisor eruption. Therefore, it was originally termed ‘tooth-lid factor’, but was later renamed EGF because it stimulated the proliferation of epithelial cells.
Since then substantial progress has been made against lung cancer over the last two decades. Research has also powered the emergence of new targeted treatments which are helping patients live a longer and higher quality life after a lung cancer diagnosis. This infographic allows the reader to dwell deeper and look closely into the history of discovery, evolution and advancements pertaining to EGFR lung cancer space.
Research and development within the cancer field is continuously evolving and progressing. This infographic highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the Food and Drug Administration in 2017.
This presentation takes the reader on an exciting journey, about the Science beneath the development of Oncology Nano Drug delivery systems. How the tumor mico and macro environments throws conspicuous challenges to the nanotech field? Furthermore, the presentation also gives a sneak view of Nanotherapeutics clinical landscape across development strategies and tumors.
This paper attempts to present situation analysis of the current marketplace of Oncology biosimilars specially with respect to the industry’s micro-environment. The research and analysis herein, intends to identify positive forces and interactions that are shaping an attractive biosimilar industry in both US and EU markets.